JUBLINGREA Q2 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,121 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
₹146 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jubilant Ingrevia delivered its highest quarterly revenue in 10 quarters at Rs 1,121 crore (+7% YoY), driven by robust 18% volume growth despite pricing headwinds. PAT surged 18% to Rs 70 crore on margin expansion in Specialty Chemicals, where EBITDA grew 50% YoY to Rs 125 crore with 26% margins. The company added 10+ new CDMO molecules in the last three quarters with peak revenue potential of Rs 1,200 crore, including the large $300 million (~$500 crore annual) agro innovator contract starting Q4 FY26. Nutrition segment faced temporary pricing pressure with margins at 12-14%, but the new cGMP plant ramp-up and EU anti-dumping duties on Chinese choline chloride create recovery visibility toward 16-18% margins. Capex of Rs 109 crore YTD toward the $300 million agro plant and new MPP in Gajraula positions the company for accelerated growth. Rs 3,500 crore peak opportunity funnel and 100+ active CDMO opportunities underpin confidence in sustaining growth trajectory. Key risks include nutrition pricing volatility and tariff-related uncertainty causing deal delays.
Colored figures show movement against the previous available record.
Guidance to track
- Reaffirmed long-term CDMO revenue target with 10 molecules already secured contributing Rs 1,200 crore peak annual revenue; expects 20-60-100% ramp-up trajectory over 3 years for most molecules.
- $300 million (~$500 crore annual) 5-year exclusive agro innovator contract expected to begin supplies in January-March 2026, contributing significantly to FY27 revenues.
- Expects nutrition segment margins to recover from current 12-14% as high-value cosmetic/food/pharma grade mix increases to 60-70% utilization levels, targeting 18-24 month ramp-up.
- Investments directed toward $300 million agro plant (Q4 commissioning), new MPP in Gajraula, Bharuch boiler, and debottlenecking existing capacity by 15-20%.
Risks flagged
- Vitamin B3 and pyrithione derivative prices experienced trough levels in Q2, impacting nutrition margins. While management expects recovery, pricing remains market-driven and unpredictable, with the next 1-2 quarters critical for confirming stabilization.
- Analyst raised concerns about US tariff announcements and India-US tensions. Management acknowledged some CDMO discussions that should have closed in 3 months are now taking 6-8 months due to short-term customer uncertainty, though long-term strategic rationale for India partnerships remains intact.
- Despite volume recovery to highest levels in 6 quarters, EBITDA remained stable QoQ as market-driven contribution erosion from lower raw material costs and oversupply continues to impact profitability in ethyl acetate and acetic anhydride.
- While management expressed optimism about capturing meaningful share of the 30,000-40,000 ton European choline chloride market following anti-dumping duties, the qualification process takes weeks to months and early Q2 orders were modest relative to business size.
Key quotes
- In the last three quarters, we have added 10 plus new molecules in our CDMO and fine chemical portfolio which have already started to show in our FY26 revenues and are expected to contribute almost 1,200 crore of peak annual revenues in coming years.
- The overall market as per our estimates is running into at least 30 to 40,000 tons [cholin chloride] and we are hopeful that as our product gets qualified in coming months and quarters we will be able to capture a meaningful portion of that.
- Only 2% of our business falls in areas where duties have been imposed and there also we are far more competitive than Chinese if you take into account all the duties which have been put on the Chinese suppliers. So in short on that business we have seen zero impact so far.
Research modules